ABSTRACT
The development of early non-invasive diagnosis methods and identification of novel biomarkers are necessary for managing Alzheimer's disease (AD) and facilitating effective prognosis and treatment. AD has multi-factorial nature and involves complex molecular mechanism, which causes neuronal degeneration. The primary challenges in early AD detection include patient heterogeneity and lack of precise diagnosis at the preclinical stage. Several cerebrospinal fluid (CSF) and blood biomarkers have been proposed to show excellent diagnosis ability by identifying tau pathology and cerebral amyloid beta (Aß) for AD. Intense research endeavors are being made to develop ultrasensitive detection techniques and find potent biomarkers for early AD diagnosis. To mitigate AD worldwide, understanding various CSF biomarkers, blood biomarkers, and techniques that can be used for early diagnosis is imperative. This review attempts to provide information regarding AD pathophysiology, genetic and non-genetic factors associated with AD, several potential blood and CSF biomarkers, like neurofilament light, neurogranin, Aß, and tau, along with biomarkers under development for AD detection. Besides, numerous techniques, such as neuroimaging, spectroscopic techniques, biosensors, and neuroproteomics, which are being explored to aid early AD detection, have been discussed. The insights thus gained would help in finding potential biomarkers and suitable techniques for the accurate diagnosis of early AD before cognitive dysfunction.
Subject(s)
Alzheimer Disease , Humans , Alzheimer Disease/diagnosis , Alzheimer Disease/pathology , Amyloid beta-Peptides , tau Proteins , Early Diagnosis , BiomarkersABSTRACT
Paclitaxel (PTX) is a microtubule inhibitor administered as an albumin-bound nanoformulation for the treatment of breast cancer. However, the effectiveness of PTX is limited by resistance mechanisms mediated in part by upregulation of the anti-apoptotic BCL-2 and P-glycoprotein (P-gp). Present investigation was designed to study the synergistic potential of NuBCP-9 and PTX loaded polymeric nanoparticles to minimize the dose and improve the efficacy and safety. PTX and NuBCP-9 loaded polylactic acid-polyethylene glycol-polypropylene glycol-polyethylene glycol [PLA-(PEG-PPG-PEG)] nanoparticles were prepared by double emulsion solvent evaporation method. PTX and NuBCP-9 loaded NPs displayed an average size of 90â¯nm with spherical morphology. PTX and NuBCP-9 dual loaded NPs reducedIC50 by ~40-fold and acted synergistically. Treatment of the syngeneic EAT mice with PTX-NuBCP-9/NPs resulted in improved efficacy than that alone treated mice. Overall, the concomitant delivery PTX and NuBCP-9 loaded NPs showed superior activity than that of PTX and NuBCP-9 alone treated mice.
Subject(s)
Nanoparticles/chemistry , Oligopeptides/chemistry , Paclitaxel/chemistry , Polymers/chemistry , Albumins/chemistry , Cell Survival/drug effects , Drug Delivery Systems/methods , Drug Synergism , Female , Humans , MCF-7 CellsABSTRACT
RBx 11760 is a bi-aryl oxazolidinone antibacterial agent active against Staphylococcus aureus but has poor solubility. Here we have encapsulated RBx 11760 in PLA-PEG NPs with an aim to improve physicochemical, pharmacokinetics and in vivo efficacy. The average size and zeta potential of RBx 11760 loaded NPs were found to be 106.4 nm and -22.2 mV, respectively. The absolute size of nanoparticles by HRTEM was found to be approximately 80 nm. In vitro antibacterial agar well diffusion assay showed clear zone of inhibition of bacterial growth. In pharmacokinetic study, nanoparticle showed 4.6-fold and 7-fold increase in AUCinf and half-life, respectively, as compared to free drug. RBx 11760 nanoparticle significantly reduced bacterial counts in lungs and improved the survival rate of immunocompromised mice as compared to free drugs. Thus, RBx 11760 loaded nanoparticles have strong potential to be used as nanomedicine against sensitive and drug resistant Staphylococcus aureus infections.
Subject(s)
Abscess/drug therapy , Bronchopneumonia/drug therapy , Groin/pathology , Lactates/chemistry , Nanoparticles/chemistry , Oxazolidinones/pharmacology , Polyethylene Glycols/chemistry , Staphylococcus aureus/pathogenicity , Abscess/microbiology , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bronchopneumonia/microbiology , Bronchopneumonia/pathology , Groin/microbiology , Immunocompromised Host , Male , Mice , Oxazolidinones/pharmacokinetics , Oxazolidinones/therapeutic use , RatsABSTRACT
Deferoxamine iron chelator has a limited therapeutic index due to rapid clearance from blood and possesses dose-limiting toxicity. Therefore, an intravenous deferoxamine delivery system based on dialdehyde cellulose (DAC) polymer was developed and its efficacy and toxicity were tested in iron-overloaded animals. The amino groups of deferoxamine were conjugated to free aldehyde moieties of dialdehyde cellulose via Schiff base reaction to form dialdehyde cellulose-deferoxamine (DAC-DFO) conjugate and characterized by Fourier transform infrared spectrophotometer, scanning electron microscope, and X-ray diffraction. The toxicity of prepared formulation was analyzed by XTT cell viability assay and LD50 study in mice. The change in serum iron levels, after intravenous administration of formulation, was observed in iron-overloaded rats. The DAC-DFO conjugate was tagged with Tc-99m to study the blood kinetics and observe change in blood circulation time. DAC-DFO conjugate was dispersible in water at concentration â¼75 mg/ml. In vitro cytotoxicity assay and LD50 study in mice indicated significantly enhanced safety of covalently bound deferoxamine (at >1000 mg/kg body weight compared to free drug at â¼270 mg/kg dose). A preliminary scintigraphy imaging and blood clearance study, with technetium-99m, indicated prolonged circulation of conjugated DFO in rabbit blood. A single dose of formulation injected into iron overloaded animals was found to maintain the normal serum iron levels until 10 days. The polymeric conjugate was effective in maintaining normal serum iron levels until 10 days at a dose of 100 mg/kg body weight.
Subject(s)
Cellulose/analogs & derivatives , Deferoxamine/administration & dosage , Deferoxamine/chemistry , Drug Carriers/chemistry , Iron/metabolism , Animals , Cellulose/administration & dosage , Cellulose/chemistry , Chemistry, Pharmaceutical/methods , Drug Carriers/administration & dosage , Iron/blood , Iron Overload/blood , Iron Overload/drug therapy , Kinetics , Male , Mice , Rabbits , Rats , Rats, Sprague-Dawley , X-Ray Diffraction/methodsABSTRACT
CdSe/CdS/ZnS and CdTe quantum dots (QDs) were synthesized by successive ion layer adsorption and reaction (SILAR) technique and direct aqueous synthesis respectively using thiol stabilizers. Synthesized CdSe/CdS/ZnS and CdTe QDs stabilized with 3-mercaptopropionic acid (MPA) and mercaptosuccinic acid (MSA) were used as fluorescent labels after conjugation with folic acid (FA) and anti-HER2 antibodies. Photoluminescence quantum yield of folated CdSe/CdS/ZnS-MPA and CdTe-MSA QDs was 59% and 77% than that of non-folated hydrophilic QDs. The folate receptor-mediated delivery of folic acid-conjugated CdTe-MSA and CdSe/CdS/ZnS-MPA QDs showed higher cellular internalization as observed by confocal laser scanning microscopic studies. Folated and non-folated CdTe-MSA QDs were highly toxic and exhibited only 10% cell viability as compared to > 80% cell viability with CdSe/CdS/ZnS-MPA QDs over the concentration ranging from 3.38 to 50 pmoles. Immunohistochemistry (IHC) results of human breast cancer tissue samples showed positive results with anti-HER2 antibody conjugated CdSe/CdS/ZnS-MPA QDs with better sensitivity and specificity as compared to conventional IHC analysis using diaminobenzedene staining.
Subject(s)
Antibodies, Neoplasm/chemistry , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Drug Delivery Systems/methods , Quantum Dots/chemistry , Receptor, ErbB-2/antagonists & inhibitors , 3-Mercaptopropionic Acid/chemistry , Animals , Cadmium Compounds/chemistry , Female , Folic Acid/chemistry , Humans , Mice , Mice, Inbred BALB C , Receptor, ErbB-2/chemistry , Receptor, ErbB-2/metabolism , Selenium Compounds/chemistry , Succinates/chemistry , Sulfides/chemistry , Tellurium/chemistry , Zinc Compounds/chemistryABSTRACT
CdSe/CdS/ZnS and CdTe quantum dots (QDs) were synthesized by successive ion layer adsorption and reaction (SILAR) technique and direct aqueous synthesis respectively using thiol stabilizers. Synthesized CdSe/CdS/ZnS and CdTe QDs stabilized with 3-mercaptopropionic acid (MPA) and mercaptosuccinic acid (MSA) were used as fluorescent labels after conjugation with folic acid (FA) and anti-HER2 antibodies. Photoluminescence quantum yield of folated CdSe/CdS/ZnS-MPA and CdTe-MSA QDs was 59% and 77% than that of non-folated hydrophilic QDs. The folate receptor-mediated delivery of folic acid-conjugated CdTe-MSA and CdSe/CdS/ZnS-MPA QDs showed higher cellular internalization as observed by confocal laser scanning microscopic studies. Folated and non-folated CdTe-MSA QDs were highly toxic and exhibited only 10% cell viability as compared to > 80% cell viability with CdSe/CdS/ZnS-MPA QDs over the concentration ranging from 3.38 to 50 pmoles. Immunohistochemistry (IHC) results of human breast cancer tissue samples showed positive results with anti-HER2 antibody conjugated CdSe/CdS/ZnS-MPA QDs with better sensitivity and specificity as compared to conventional IHC analysis using diaminobenzedene staining.
Subject(s)
Antibodies, Monoclonal/chemistry , Breast Neoplasms/diagnostic imaging , Folic Acid/chemistry , Quantum Dots/chemistry , Receptor, ErbB-2/antagonists & inhibitors , 3-Mercaptopropionic Acid , Cadmium Compounds/chemistry , Fluorescence , Humans , Microscopy, Confocal , Staining and Labeling , SulfidesABSTRACT
Cosmeceuticals have gained great importance and are among the top-selling products used for skin care. Because of changing lifestyles, climate, and increasing pollution, cosmeceuticals are utilized by every individual, thereby making cosmeceuticals a fruitful field for research and the economy. Cosmeceuticals provide incredibly pleasing aesthetic results by fusing the qualities of both cosmetics and medicinal substances. Cosmeceuticals are primarily utilized to improve the appearance of skin by making it smoother, moisturized, and wrinkle-free, in addition to treating dermatological conditions, including photoaging, burns, dandruff, acne, eczema, and erythema. Nanocosmeceuticals are cosmetic products that combine therapeutic effects utilizing nanotechnology, allowing for more precise and effective target-specific delivery of active ingredients, and improving bioavailability.
Subject(s)
Cosmeceuticals , Nanotechnology , Skin Care , Humans , Cosmeceuticals/administration & dosage , Skin Care/methods , Nanotechnology/methods , Skin Diseases/drug therapy , Skin Diseases/therapy , Cosmetics/administration & dosage , Administration, Cutaneous , Skin Aging/drug effects , Animals , Drug Delivery Systems/methods , Dermatologic Agents/administration & dosage , Skin/metabolism , Skin/drug effects , Biological Availability , NanoparticlesABSTRACT
In modern drug discovery, numerous assay formats are available to screen and quantitate receptor-ligand interactions. Radioactive assays are "gold standard" because they are fast, easy, and reproducible; however, they are hazardous, produce radioactive waste, require special lab conditions, and are expensive on a large scale. Thus, it provides a lot of importance to the "mix & measure" assays that have an optical readout. Fluorescence techniques are likely to be among the most important detection approaches used for high throughput screening due to their high sensitivity and amenability to automation. The aim of the present study was to determine the functional antagonistic affinities of standard muscarinic antagonists in CHO cells over expressing m1, m3, and m5 receptors and to compare them with the respective binding affinities. This study was further extended to elucidate that Ca+2 measurement assays can serve as a functional screening tool for GPCRs. For this purpose, standard muscarinic receptor antagonists, namely, tolterodine, oxybutynin, and atropine were used. We determined and compared the IC50 values of these three standard inhibitors in fura 2 AM loaded m1, m3, and m5 overexpressing CHO cells and in radioligand binding assay. Both the assays exhibited comparable rank order potencies of the standard inhibitors. This study suggests that Ca+2 mobilization assays can be an alternate to radioligand binding assays.
Subject(s)
Calcium/analysis , Fluorometry/methods , Muscarinic Antagonists/pharmacology , Receptor, Muscarinic M1/antagonists & inhibitors , Receptor, Muscarinic M3/antagonists & inhibitors , Receptor, Muscarinic M5/antagonists & inhibitors , Animals , Atropine/pharmacology , Benzhydryl Compounds/pharmacology , CHO Cells , Cresols/pharmacology , Cricetinae , Cricetulus , Fluorescence , Fluorescent Dyes/pharmacology , Fluorometry/instrumentation , Fura-2/analogs & derivatives , Fura-2/pharmacology , Humans , Mandelic Acids/pharmacology , Phenylpropanolamine/pharmacology , Radioligand Assay , Receptor, Muscarinic M1/metabolism , Receptor, Muscarinic M3/metabolism , Receptor, Muscarinic M5/metabolism , Scopolamine Derivatives/antagonists & inhibitors , Scopolamine Derivatives/metabolism , Tolterodine Tartrate , TransfectionABSTRACT
The cDNA encoding PDE10A (phosphodiesterase 10A) was cloned and a stable recombinant HEK-293 (human embryonic kidney-293) cell line expressing high levels of PDE10A was generated. Transient transfection of pCRE-Luc plasmid, harbouring the luciferase reporter gene under the control of CRE (cAMP-response element)-binding sequence, into the stable recombinant cell line, followed by treatment with PDE10 inhibitor, resulted in a dose-dependent increase in luciferase activity. This method provides a simple and sensitive cell-based assay for screening of PDE10 inhibitors for development of novel therapeutics for the treatment of neurological disorders.
Subject(s)
Biological Assay/methods , Biosensing Techniques/methods , Kidney/drug effects , Kidney/metabolism , Phosphodiesterase Inhibitors/administration & dosage , Phosphoric Diester Hydrolases/metabolism , Spectrometry, Fluorescence/methods , Cell Line , Humans , Luminescent Measurements/methods , Phosphodiesterase Inhibitors/analysis , Recombinant Proteins/metabolismABSTRACT
PURPOSE: The MUC1-C oncoprotein is an intracellular target that is druggable with cell-penetrating peptide inhibitors. However, development of peptidyl drugs for treating cancer has been a challenge because of unfavorable pharmacokinetic parameters and limited cell-penetrating capabilities. EXPERIMENTAL DESIGN: Encapsulation of the MUC1-C inhibitor GO-203 in novel polymeric nanoparticles was studied for effects on intracellular targeting of MUC1-C signaling and function. RESULTS: Our results show that loading GO-203 into tetrablock polylactic acid (PLA)-polyethylene glycol (PEG)-polypropylene glycol (PPG)-PEG copolymers is achievable and, notably, is enhanced by increasing PEG chain length. In addition, we found that release of GO-203 from these nanoparticles is controllable over at least 7 days. GO-203/nanoparticle treatment of MUC1-C-positive breast and lung cancer cells in vitro was more active with less frequent dosing than that achieved with nonencapsulated GO-203. Moreover, treatment with GO-203/nanoparticles blocked MUC1-C homodimerization, consistent with on-target effects. GO-203/nanoparticle treatment was also effective in downregulating TIGAR, disrupting redox balance, and inhibiting the self-renewal capacity of cancer cells. Significantly, weekly administration of GO-203/nanoparticles to mice bearing syngeneic or xenograft tumors was associated with regressions that were comparable with those found when dosing on a daily basis with GO-203. CONCLUSIONS: These findings thus define an effective approach for (i) sustained administration of GO-203 in polymeric PLA-(PEG-PPG-PEG) nanoparticles to target MUC1-C in cancer cells and (ii) the potential delivery of other anticancer peptide drugs.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Ehrlich Tumor/drug therapy , Mucin-1/metabolism , Nanocapsules/administration & dosage , Peptides/administration & dosage , Amino Acid Sequence , Animals , Antineoplastic Agents/chemistry , Carcinoma, Ehrlich Tumor/pathology , Cell Line, Tumor , Cell Self Renewal/drug effects , Cell Survival/drug effects , Drug Compounding , Humans , Mice, Inbred BALB C , Molecular Sequence Data , Molecular Targeted Therapy , Nanocapsules/chemistry , Oxidation-Reduction , Peptides/chemistry , Protein Multimerization , Tumor Burden/drug effects , Xenograft Model Antitumor AssaysABSTRACT
The preclinical development of peptidyl drugs for cancer treatment is hampered by their poor pharmacologic properties and cell penetrative capabilities in vivo. In this study, we report a nanoparticle-based formulation that overcomes these limitations, illustrating their utility in studies of the anticancer peptide NuBCP-9, which converts BCL-2 from a cell protector to a cell killer. NuBCP-9 was encapsulated in polymeric nanoparticles composed of a polyethylene glycol (PEG)-modified polylactic acid (PLA) diblock copolymer (NuBCP-9/PLA-PEG) or PEG-polypropylene glycol-PEG-modified PLA-tetrablock copolymer (NuBCP-9/PLA-PEG-PPG-PEG). We found that peptide encapsulation was enhanced by increasing the PEG chain length in the block copolymers. NuBCP-9 release from the nanoparticles was controlled by both PEG chain length and the PLA molecular weight, permitting time-release over sustained periods. Treatment of human cancer cells with these nanoparticles in vitro triggered apoptosis by NuBCP-9-mediated mechanism, with a potency similar to NuBCP-9 linked to a cell-penetrating poly-Arg peptide. Strikingly, in vivo administration of NuBCP-9/nanoparticles triggered complete regressions in the Ehrlich syngeneic mouse model of solid tumor. Our results illustrate an effective method for sustained delivery of anticancer peptides, highlighting the superior qualities of the novel PLA-PEG-PPG-PEG tetrablock copolymer formulation as a tool to target intracellular proteins.
Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Ehrlich Tumor/drug therapy , Nanocapsules/chemistry , Oligopeptides/pharmacology , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/metabolism , Apoptosis , Carcinoma, Ehrlich Tumor/pathology , Cell Proliferation/drug effects , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/metabolism , Delayed-Action Preparations/pharmacology , Drug Screening Assays, Antitumor , Hep G2 Cells , Humans , Inhibitory Concentration 50 , Lactates/chemistry , MCF-7 Cells , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Oligopeptides/chemistry , Oligopeptides/metabolism , Particle Size , Polyethylene Glycols/chemistry , Propylene Glycols/chemistry , Proto-Oncogene Proteins c-bcl-2/metabolism , Tumor Burden/drug effectsABSTRACT
Delivering peptides into cells targeting the undruggable oncoproteins is an emerging area in cancer therapeutics. Here we report a novel nanoparticle-based delivery system that can transport therapeutic cargos to the intracellular sites without the need for a cell transduction or penetration domain (CPP). In the present study, we have used iron oxide nanoparticles to deliver an oncopeptide, NuBCP-9, targeting the BCL-2 BH3 domain. Citric acid/2-bromo 2-methylpropanoic acid (CA/BMPA)-capped SPIONs were used to immobilize and deliver the NuBCP-9 peptide to the cancer cells without any noticeable off-target effects. Our results have demonstrated that NuBCP-9-SPIONs efficiently penetrate into cancer cells and bind to its intracellular target protein BCL-2. Moreover, significant inhibition of proliferation and substantial induction of cell death were observed when cancer cells were treated with NuBCP-9-SPIONs at different time intervals. Importantly, the IC50 values for killing of breast cancer cells with NuBCP-9-SPIONs were much lower compared to cells treated with the NuBCP-9 peptide linked with a CPP (Arg-8; NuBCP-9-R8). Molecular and biochemical analyses further supported that NuBCP-9-SPIONs killed breast cancer cells by apoptosis-mediated mechanisms. Furthermore, our data demonstrated that administration of NuBCP-9-SPIONs to mice bearing Ehrlich ascites tumors (EAT) was associated with loss of tumorigenicity and extensive apoptosis in tumor tissues. Taken together, these findings show that a non-CPP-tagged peptide can be successfully delivered to undruggable intracellular oncotargets using SPIONs.
Subject(s)
Apoptosis/drug effects , Carcinoma, Ehrlich Tumor/drug therapy , Cell Proliferation/drug effects , Ferric Compounds , Nanoparticles/chemistry , Oligopeptides , Animals , Carcinoma, Ehrlich Tumor/metabolism , Carcinoma, Ehrlich Tumor/pathology , Drug Carriers , Female , Ferric Compounds/chemistry , Ferric Compounds/pharmacology , Hep G2 Cells , Humans , Mice , Mice, Inbred BALB C , Oligopeptides/chemistry , Oligopeptides/pharmacology , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/metabolismABSTRACT
RNA interference (RNAi) is a sequence-specific, post-transcriptional gene silencing mechanism in animals and plants, which is mediated by double-stranded RNA (dsRNA). There has recently been an increasing interest in harnessing the gene silencing activity of dsRNA to develop novel drugs for the treatment of various diseases, such as cancer, neurological disorders, age-related macular degeneration and viral infections. Small interfering RNA (siRNA)-based drugs have distinct advantages over conventional small molecule or protein-based drugs, including high specificity, higher potency and reduced toxicity. However, there are several technical obstacles to overcome before siRNA-based drugs reach the clinic. Delivery of siRNA to the target tissues and stability in the serum remain a major challenge and are the main focus of current research and development efforts. This review focused primarily on the progress made in developing RNAi as therapeutics for cancer and the challenges associated with its clinical development. Use of ligands recognizing cell-specific receptors to achieve tumor-specific delivery of siRNA, methods for enhanced siRNA delivery, improving the bioavailability and pharmacokinetic properties of siRNA and reducing the off-target effects and non-specific gene silencing are discussed in the light of current evidence.
Subject(s)
Neoplasms/therapy , RNA Interference , RNA, Small Interfering/therapeutic use , Animals , Clinical Trials as Topic , Humans , Neoplasms/genetics , RNA, Small Interfering/adverse effects , RNA, Small Interfering/pharmacokineticsABSTRACT
In this study we test whether functional screening of compounds to adrenergic G protein-coupled receptors (GPCRs) would provide data that correlated significantly with radiolabeled binding data, thereby permitting researchers to replace expensive radioligand-binding experiments with non-radioactive screening. An increase in intracellular calcium levels represents an important second messenger signal for several recombinant GPCRs. In this study, we describe the affinities of three alpha adrenoceptor antagonists (terazosin, tamsulosin and alfuzosin), determined by monitoring the changes in intracellular calcium levels and comparing them with their radioligand-binding affinities. In addition to determining the functional affinities of the three alpha adrenoceptor antagonists, we evaluate their binding at two alpha adrenoceptor subtypes and optimized the assay for high-throughput screening.
Subject(s)
Biotechnology/methods , Fluorometry/instrumentation , Animals , Calcium/chemistry , Calcium/metabolism , Cell Line , Dose-Response Relationship, Drug , Fluorescent Dyes/pharmacology , Fluorometry/methods , GTP-Binding Proteins/chemistry , Humans , Kinetics , Prazosin/analogs & derivatives , Prazosin/pharmacology , Protein Binding , Quinazolines/pharmacology , Receptors, Adrenergic/metabolism , Signal Transduction , Sulfonamides/pharmacology , TamsulosinABSTRACT
Phosphodiesterases (PDEs) constitute a superfamily of enzymes that plays an important role in signal transduction by catalysing the hydrolysis of cAMP and cGMP. cDNA encoding PDE7A1 subtype was cloned and a stable recombinant HEK 293 cell line expressing high levels of PDE7A1 was generated. Transient transfection of pCRE-Luc plasmid, harboring luciferase reporter gene into the stable recombinant cell line and subsequent treatment with PDE7 inhibitor, resulted in a dose-dependent increase in luciferase activity. This method provides a simple and sensitive cell-based assay for screening of PDE7 selective inhibitors for the treatment of T cell mediated diseases.
Subject(s)
Cyclic Nucleotide Phosphodiesterases, Type 7/antagonists & inhibitors , Cyclic Nucleotide Phosphodiesterases, Type 7/biosynthesis , Phosphodiesterase Inhibitors/pharmacology , Cell Line , Cloning, Molecular , Cyclic Nucleotide Phosphodiesterases, Type 7/genetics , Drug Evaluation, Preclinical/methods , Gene Expression , Genes, Reporter , Humans , Luciferases/genetics , Luciferases/metabolismABSTRACT
Phosphodiesterase (PDE) constitutes a superfamily of enzymes that catalyze the hydrolysis of cAMP and cGMP into their corresponding monophosphates and play an important role in diverse physiological functions. The present study provides a process for identifying PDE4 subtypes selective inhibitors using a reporter gene assay. Stable recombinant HEK-293 cell lines expressing high levels of PDE4A4B, PDE4B2A, and PDE4D3 subtypes individually were generated. Transient transfection of pCRE-Luc plasmid, harboring luciferase reporter gene under the control of cAMP response element (CRE)-binding sequence, into these stable recombinant cell lines followed by treatment with PDE4 inhibitor, resulted in a dose dependent increase in luciferase activity. This methods provide a novel, simple and sensitive assay for high throughput screening of PDE4 subtype selective inhibitors for treatment of asthma and COPD.
Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Luciferases/metabolism , Phosphodiesterase Inhibitors/pharmacology , 3',5'-Cyclic-AMP Phosphodiesterases/genetics , 3',5'-Cyclic-AMP Phosphodiesterases/metabolism , Aminopyridines/pharmacology , Benzamides/pharmacology , Cell Line , Cloning, Molecular , Cyclic AMP/metabolism , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic Nucleotide Phosphodiesterases, Type 4 , Cyclopropanes/pharmacology , Cytoplasm/enzymology , Dose-Response Relationship, Drug , Humans , Immunohistochemistry , Isoenzymes/antagonists & inhibitors , Isoenzymes/genetics , Isoenzymes/metabolism , Kinetics , Luciferases/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Regulatory Sequences, Nucleic Acid , Rolipram/pharmacology , Transfection , U937 CellsABSTRACT
The cDNAs encoding for three subtypes of adrenergic receptors, alpha1A-, alpha1B- and alpha1D-ARs, were cloned and expressed in HEK 293 cells. Expression of alpha1A- and alpha1B-AR subtypes in HEK 293 cells was stable even with increased passages but that of alpha1D-AR was not. Cellular localization studies using immunofluorescence and flow cytometry revealed that expression of alpha1A- and alpha1B-ARs was primarily localized on the cell membrane whereas expression of alpha1D-AR was predominantly intracellular. Our studies clearly demonstrated that the culturing of the recombinant cell lines expressing alpha1D-AR in charcoal/dextran treated fetal bovine serum (FBS) resulted in targeting of alpha1D-AR to the cell membrane and thus, significantly improving its stability and availability for ligand binding studies.
Subject(s)
Culture Media/chemistry , Culture Media/pharmacology , Gene Expression Regulation/drug effects , Receptors, Adrenergic, alpha-1/metabolism , Recombinant Proteins/metabolism , Cell Culture Techniques , Cell Line , Cell Membrane/metabolism , Cells, Cultured , Charcoal/pharmacology , Cloning, Molecular , DNA, Complementary/isolation & purification , Dextrans/pharmacology , Embryo, Mammalian/cytology , Fetal Blood/chemistry , Flow Cytometry , Humans , Kidney/cytology , Receptors, Adrenergic, alpha-1/genetics , Recombinant Proteins/genetics , Serum/chemistryABSTRACT
cDNAs encoding for five mAChR subtypes (M1-M5) were cloned under different promoters in various eukaryotic vectors and each subtype was expressed in different mammalian cell lines. CHO-K1 cell line was the best for generating stable cell lines expressing muscarinic receptors. Immunofluorescence and flow cytometry revealed that expression of M1-M5 was primarily localized on the cell membrane. Western blotting and radio-ligand binding studies revealed that expression of each receptor was stable at higher passages.